Molecular Mechanisms of Liver Fibrosis (Diversity Supplement)

肝纤维化的分子机制（多样性补充）

• 批准号: 10402533
• 负责人: VIJAY H. SHAH
• 金额: $ 12.01万
• 依托单位: MAYO CLINIC ROCHESTER
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-05-10 至 2022-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10402533
• 关键词: Affect; Alcohols; Applications Grants; Biomedical Research; Cellular biology; Chemistry; Cirrhosis; Clinical; Development; Development Plans; Disease model; Doctor of Philosophy; Educational workshop; Epigenetic Process; Fibrosis; Goals; Grant; Hepatic Stellate Cell; Journals; Knowledge; Lead; Learning; Liver Fibrosis; Liver diseases; Mentors; Methodology; Minnesota; Molecular; Molecular Biology; Molecular Genetics; Morbidity - disease rate; National Institute on Alcohol Abuse and Alcoholism; Paper; Pharmacology; Prevention; Publications; Regulatory Pathway; Techniques; Training; Translating; United States National Institutes of Health; Universities; Work; alcohol abuse therapy; base; biological systems; career development; clinical application; design; experimental study; fibrogenesis; frontier; inhibitor/antagonist; meetings; member; migration; mortality; novel; public health relevance; symposium; tool

Project Summary/Abstract This diversity supplement to the NIAAA R37 grant is in support of the candidate Dr. Amani Lee. Dr. Amani Lee will pharmacologically inhibit epigenetic regulators of the mobility and matrix formation of hepatic stellate cells (HSCs). He will work with both commercial inhibitors (e.g. Tazemetostat, iBET151) and novel inhibitors, developed by collaborators at the University of Minnesota, to elucidate downstream effects that will influence activation/migration and matrix formation for HSCs. Co-inhibition is hypothesized to reduce both the migration of HSCs and fibrogenesis in liver disease models. In total, this approach has the potential to identify downstream targets that converge two regulatory pathways, as well as, highlight the potential for a pharmacological co-treatment of alcohol-associated liver fibrosis. This supplement will combine Dr. Lee’s expertise in chemistry with his desire to learn how to translate frontier biomedical research into effective and practical clinical applications. Given his PhD, he will independently function in bench-based experimentation and develop methodology necessary to advance the project. He will also be trained in advanced molecular genetics and cell biology techniques by lab members in the Shah Lab. Additionally he will have the opportunity to audit workshops and short courses at Mayo to enhance his background knowledge of molecular biology and epigenetics. Dr. Shah will have weekly one-on-one meetings with Dr. Lee, in addition to quarterly meetings, where they will review Dr. Lee’s career development plans. Furthermore, Dr. Lee will be co-mentored in how to find, draft, and submit grant applications, clinical journal papers, and conference publications. It is our goal that within 24 months of approval Dr. Lee will be well-suited to apply for NIH grants (e.g., F32), as well as, obtain the tools to design his own experiments on biological systems affected by alcohol-associated liver disease.

项目概要/摘要 NIAAA R37 拨款的多样性补充是为了支持候选人 Amani Lee 博士。 Amani Lee 博士将从药理上抑制流动性和基质的表观遗传调节剂 他将使用两种商业抑制剂（例如，肝星状细胞（HSC）的形成）。 Tazemetostat、iBET151）和新型抑制剂，由大学合作者开发 明尼苏达州，阐明影响激活/迁移和基质的下游效应 重新捕获 HSC 的形成，以减少 HSC 的迁移和 总的来说，这种方法有可能识别肝病模型中的纤维发生。 融合两种监管途径的下游目标，以及强调的潜力 该补充剂将结合酒精相关肝纤维化的药物联合治疗。 李博士在化学方面的专业知识以及他对学习如何转化前沿生物医学的渴望 获得博士学位后，他将独立研究有效和实际的临床应用。 在基于实验室的实验中发挥作用，并开发必要的方法来推进 他还将接受实验室先进分子遗传学和细胞生物学技术的培训。 此外，他还将有机会旁听研讨会和短片。 梅奥博士的课程，以增强他的分子生物学和表观遗传学背景知识。 除了季度会议外，沙阿还将与李博士每周举行一对一会议，其中 他们将审查李博士的职业发展计划，此外，李博士将接受共同指导。 如何查找、起草和提交资助申请、临床期刊论文和会议 我们的目标是在批准后 24 个月内李博士将非常适合申请。 获得 NIH 资助（例如 F32），以及获得设计自己的生物实验的工具 受酒精相关肝病影响的系统。